305 related articles for article (PubMed ID: 19000276)
1. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs.
Sedlacek HS; Ramsey DS; Boucher JF; Eagleson JS; Conder GA; Clemence RG
J Vet Pharmacol Ther; 2008 Dec; 31(6):533-7. PubMed ID: 19000276
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
Ramsey DS; Kincaid K; Watkins JA; Boucher JF; Conder GA; Eagleson JS; Clemence RG
J Vet Pharmacol Ther; 2008 Dec; 31(6):538-43. PubMed ID: 19000277
[TBL] [Abstract][Full Text] [Related]
3. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.
de la Puente-Redondo VA; Siedek EM; Benchaoui HA; Tilt N; Rowan TG; Clemence RG
J Small Anim Pract; 2007 Feb; 48(2):93-8. PubMed ID: 17286662
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.
de la Puente-Redondo VA; Tilt N; Rowan TG; Clemence RG
Am J Vet Res; 2007 Jan; 68(1):48-56. PubMed ID: 17199418
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
Conder GA; Sedlacek HS; Boucher JF; Clemence RG
J Vet Pharmacol Ther; 2008 Dec; 31(6):528-32. PubMed ID: 19000275
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
Hickman MA; Cox SR; Mahabir S; Miskell C; Lin J; Bunger A; McCall RB
J Vet Pharmacol Ther; 2008 Jun; 31(3):220-9. PubMed ID: 18471143
[TBL] [Abstract][Full Text] [Related]
7. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients.
Vail DM; Rodabaugh HS; Conder GA; Boucher JF; Mathur S
Vet Comp Oncol; 2007 Mar; 5(1):38-46. PubMed ID: 19754800
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs.
Yalcin E; Keser GO
J Vet Pharmacol Ther; 2017 Dec; 40(6):599-603. PubMed ID: 28198032
[TBL] [Abstract][Full Text] [Related]
10. Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis.
Kantyka ME; Meira C; Bettschart-Wolfensberger R; Hartnack S; Kutter APN
J Vet Emerg Crit Care (San Antonio); 2020 Jul; 30(4):436-441. PubMed ID: 32515910
[TBL] [Abstract][Full Text] [Related]
11. In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis.
Kretzing S; Abraham G; Seiwert B; Ungemach FR; Krügel U; Teichert J; Regenthal R
Arch Toxicol; 2011 Dec; 85(12):1565-73. PubMed ID: 21626407
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs.
Rau SE; Barber LG; Burgess KE
J Vet Intern Med; 2010; 24(6):1452-7. PubMed ID: 21039869
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
Benchaoui HA; Cox SR; Schneider RP; Boucher JF; Clemence RG
J Vet Pharmacol Ther; 2007 Aug; 30(4):336-44. PubMed ID: 17610407
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs.
Hay Kraus BL
J Am Vet Med Assoc; 2014 May; 244(10):1164-9. PubMed ID: 24786163
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the antiemetic efficacy of maropitant in dogs medicated with morphine and acepromazine.
Lorenzutti AM; Martín-Flores M; Litterio NJ; Himelfarb MA; Zarazaga MP
Vet Anaesth Analg; 2016 Mar; 43(2):195-8. PubMed ID: 26095960
[TBL] [Abstract][Full Text] [Related]
16. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
Lorenzutti AM; Martín-Flores M; Litterio NJ; Himelfarb MA; Invaldi SH; Zarazaga MP
Can Vet J; 2017 Jan; 58(1):35-38. PubMed ID: 28042152
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
[TBL] [Abstract][Full Text] [Related]
18. The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.
de la Puente-Redondo V; Tingley FD; Schneider RP; Hickman MA
J Vet Pharmacol Ther; 2007 Aug; 30(4):281-7. PubMed ID: 17610400
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.
Benchaoui HA; Siedek EM; De La Puente-Redondo VA; Tilt N; Rowan TG; Clemence RG
Vet Rec; 2007 Sep; 161(13):444-7. PubMed ID: 17906225
[TBL] [Abstract][Full Text] [Related]
20. Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine.
Sharun K; Jambagi K; Arya M; Aakanksha ; Chaithra SN; Patel PK; Dixit SK; Dhama K
Arch Razi Inst; 2021 Nov; 76(5):1175-1182. PubMed ID: 35355772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
